Search Icon of a magnifying glass. In Septemberthe independent pharmacy Valisure wrote a letter to the U. Food and Drug Administration FDA regarding the safety of the heartburn medication Zantac and its generic counterparts.
Multidistrict Litigation MDL : The consolidation of complex federal cases for management in a single court, designed to speed the process. This is a serious health risk as NDMA has been suggested to be linked to occurrences of:.
In the lawsuit, plaintiffs have claimed to have contracted cancers of the colon, esophagus, breast, bladder and more. With more and more cases arising, in early the Judicial Panel on Multidistrict Litigation JPML had to decide whether to consolidate all of these claims. On Feb. District Judge Robin Rosenberg of Miami. By Feb. Legal experts expect that before the Zantac multidistrict litigation has concluded, at leastclaimants will come forward.
Those same experts expect that Rosenberg will more likely oversee a settlement than a drawn-out trial. James Parker is a news writer and fact-checker from Coral Springs, Florida. When he's not writing, he enjoys rewatching "Almost Famous" or curling up with a good book. Canada is facing shortages of heartburn medications after a Zantac recall led to an increase in demand for alternatives. A Florida woman has filed a lawsuit alleging that Zantac manufacturers deliberately allowed an unsafe product to remain on the market.
A citizen petition requesting a total suspension of ranitidine products has been submitted to the FDA. Newspaper News. Investigations Icon of an eye Investigations. Connect Connect.
Zantac Mesh Breast Implants Roundup. Notice something we are missing?Interested in this case? Sign up to receive real-time updates. Thumbnails Document Outline Attachments. Highlight all Match case. Toggle Sidebar. Zoom Out. More Information Less Information.
Enter the password to open this PDF file:. Cancel OK. File name:. File size:. Title:. Author:. Subject:. Keywords:. Creation Date:. Modification Date:. Creator:.
PDF Producer:. PDF Version:.
MDL Panel Sends Zantac Lawsuits to Florida
Page Count:. Preparing document for printing…. Sanofi-Aventis U. LLC, et al. Scola Jr. As set forth in more detail below, Plaintiff Kerzer agrees that coordination or consolidation is appropriate but submits that coordination in the Southern District of Florida is most appropriate. Pursuant to Sectioncentralization is appropriate when one or more common questions of fact are pending in different districts; a transfer would serve the convenience of parties and 1 Case MDL No.
The present case satisfies all conditions for transfer. See, e. In addition, all of the actions will share factual questions regarding general causation and the background science regarding the role that the NDMA may play in causing cancers or other injuries. Common regulatory issues also exist, as all actions stem from the same FDA investigation and the subsequent recall announced by numerous brand-name and generic manufacturers including, e.
The undersigned is aware of at least 29 substantially similar personal injury and class actions 2 in at least 13 different federal district courts, including: 1. Southern District of Florida 2.In the legal profession, information is the key to success. Law provides the intelligence you need to remain an expert and beat the competition. Already a subscriber? Click here to login. Enter your details below and select your area s of interest to stay ahead of the curve and receive Law's daily newsletters.
Zantac MDL (multi-district litigation) - Legal Claims for Cancer Caused by NDMA
Create custom alerts for specific article and case topics and so much more! Attached Documents. I'm Law's automated support bot. How can I help you today? For example, you can type: I forgot my password I took a free trial but didn't get a verification email How do I sign up for a newsletter? Get instant access to the one-stop news source for business lawyers Register Now!With a growing number of Zantac lawsuits being filed on behalf of individuals exposed to cancer-causing chemicals produced by the popular heartburn drug, several major drug manufacturers indicate they agree the claims should be consolidated before one federal judge for coordinated pretrial proceedings.
Over the past few months, dozens of product liability complaints have been filed against manufacturers of various forms of Zantac, alleging that high levels of Nitrosodimethylamine NDMA are released by ranitidine contained in the drug, which may increase the risk of bladder cancer, kidney cancer, colorectal cancer, stomach cancer and other forms of cancer along the digestive tract. To avoid duplicative discovery into common issues in the Zantac litigation, prevent conflicting pretrial rulings and serve the convenience of the parties, witnesses and the judicial system, a group of six plaintiffs filed a motion last month, which calls for all Zantac claims to be centralized in the U.
In recent weeks, a number of responses have been filed by different plaintiffs proposing alternative venues, including the Southern District of Florida, Eastern District of Tennessee, Middle District of Tennessee, Northern District of Illinois, Northern District of California and other locations. The drug makers indicate there are currently at least 45 product liability lawsuits over Zantac pending throughout the federal court system, including 30 personal injury cases and 15 class action lawsuits.
However, as Zantac injury lawyers continue to review and file claims for individuals nation wide, it is widely expected that several thousand claims may eventually be filed, given the widespread use of Zantac since the early s. The U. While the outcome of such early trials will not be binding in other cases, they may help the parties reach Zantac settlements, avoiding the need for potentially hundreds or thousands of individual trials in courts throughout the U.
NOTE: Providing information for review by an attorney does not form an attorney-client relationship. Twitter Facebook. This field is for validation purposes and should be left unchanged. Yes No. Provide additional contact information if you want an attorney to review your comments and contact you about a potential case.
This information will not be published.Sign In Register. Docket alerts are an advanced feature of CourtListener. Monthly donors can create unlimited docket alerts. If you are not a monthly donor, we allow five alerts and give a bonus of 10 alerts to anybody with the RECAP Extension installed.
You currently have alerts. We can sometimes provide need-based exceptions to these rules. If you might need an exception, please let us know. Search this Docket. Last Updated: not the date of the latest filing in this case. Date Filed: Nov. Date of Last Known Filing: Jan. MLD Status: Pending. In their briefs, the parties should address what steps they have taken to pursue alternatives to centralization including, but not limited to, engaging in informal coordination of discovery and scheduling, and seeking Section transfer of one or more of the subject cases.
Signed by Clerk of the Panel John W. Mark Allan Blake, Walter H. Ferraro, Jr. LLC, and Chattem, Inc. Berman, Esq. Attachments: 1 Exhibit Feigelstock, and Sharon S. Levi Y. The parties to actions on the motion s remain under a duty, pursuant to Panel Rules 6. Parties in any potential tag-along action may file an Interested Party response, but must do so promptly, and in any event, no later than the Thursday prior to the hearing session at which the motion for transfer is to be heard by the Panel.
Jacquet, Anthony K. Micle Sr. Signed by Judge Karen K.This was initially formed on February 6 with just 15 cases. At least cases are pending throughout the country in 21 districts with the expectation that more plaintiffs will join sooner rather than later. More information concerning this consolidated lawsuit should be available after the 1 st pretrial conference. It is expected that after the MDL process is complete, which will take some time, it will enable settlements to take place for the plaintiffs.
Glaxo Holdings Ltd.
Zantac Users Pile On Cancer Claims Ahead Of JPML Hearing
It took 37 years to realize that Zantac and some other medications used to treat heartburn could contain N-Nitrosodimethylamine NDMA in unsafe amounts. These amounts classify NDMA as a probable human carcinogen which has links to certain cancers such as:. It is difficult to assess exactly how much harm these drugs have inflicted on the consumer as it is partly dependent on how long they have been on the market.
Also, the causes of high NMDA levels have to be considered as well. A study published recently has suggested that the contamination may not have been as a result of the manufacturing process as such but it could be due to a combination of time and heat. This could take place while the medications are in their packaging sitting around in storage or on shelves for a long time after they were initially analyzed by the manufacturers.
The drug of course could be simply dangerous in itself, or just inherently unstable. Even though there is very clear evidence that Zantac contains NDMA at toxic levels, the FDA still allows these ranitidine based medications to be sold publicly.
Over the last few months, however, some pharmacies and manufacturers have voluntarily reduced the amount of the product, but typically it is difficult to assess accurately just how many consumers have been made ill by the products. There are likely to be more and more victims coming forward to file lawsuits against manufacturers for not taking seriously the fact that they have been providing a defective drug which is likely to cause harm to users.
It is expected the Zantac MDL will follow a similar pattern. As soon as the MDL is initiated it goes through a 1 st stage which is called discovery. During this period both the plaintiffs and defendants gather the facts they need and use this as evidence. Two key questions need to be answered which are:. To be able to answer these questions accurately, both the plaintiffs and defendants may call upon expert witnesses who have the knowledge to interpret the scientific evidence available.
After a while, the court may select at least one case for trial. These sorts of trials are a way of testing the strength of any evidence, witness testimonies and arguments presented before a jury.
Following a successful bellwether trial, the last remaining cases usually reach a settlement, or they are transferred to home states where they await individual trials. Whatever the route a particular Zantac lawsuit ends up taking, the MDL may have useful advantages.
It takes a long time but the plaintiff could gain substantially from the process of shared discovery. If the bellwether trial resembles a specific lawsuit, it may offer clear guidance for the terms of a settlement.
The outcome can speed up settlement for a defendant who can see there is little use proceeding to a trial. If you, or a family member, have been injured by using Zantac, you should contact Coffey Trial Lawyers who will evaluate your case and decide if there is sufficient evidence to file a lawsuit. Your email address will not be published. Save my name, email, and website in this browser for the next time I comment. Skip to content Blog. How many victims were affected by Zantac? These amounts classify NDMA as a probable human carcinogen which has links to certain cancers such as: stomach cancer rectal cancer pancreatic cancer ovarian cancer kidney cancer liver cancer intestinal cancer esophageal cancer colon cancer bladder cancer It is difficult to assess exactly how much harm these drugs have inflicted on the consumer as it is partly dependent on how long they have been on the market.
What could cause heat exposure to Zantac? Two key questions need to be answered which are: What is the scientific link is between the medication and the harm it has inflicted?Recently, contamination triggered widespread recalls of Zantac heartburn medication.
Laboratory testing recently found a cancer-causing substance in Zantac ranitidine heartburn medication. Animal testing has linked the contaminant, n-nitrosodimethylamine NDMAto several forms of cancer. The U. The agency responded by enacting new testing requirements for the drug.
At this time, all contaminated lots of the drug have been recalled. If manufacturers find contamination in the future, those lots will also be recalled. Several companies manufacture Zantac and generic ranitidine. One of those manufacturers recently reported multi-million dollar losses associated with the drug.Zantac and its generic version found with chemical that could lead to cancer
The company also reported a Several other global manufacturers recalled their own Zantac products. But none aside from Sanofi have announced the financial impact of the recalls. Given the 16 million-plus yearly prescriptions for Zantac and ranitidine, the other manufacturers likely suffered substantial losses as well. In addition to their financial troubles, Zantac manufacturers must deal with new developments on the legal front.
Days ago, more than Zantac lawsuits were merged into multidistrict litigation MDL. District Judge Robin Rosenberg will preside. Creation of the Zantac MDL will substantially simplify the process of trying hundreds, if not thousands, of related cases.
It will likely be months or years before we see the first Zantac lawsuit go to trial, though. In crafting a case for legal damages from NDMA-contaminated Zantac, legal teams had a couple of options. They could focus on either of two possible sources for the carcinogen:. Manufacturers were unaware of the potential for NDMA contamination.
So they did not test the final product for the carcinogen. Consumers were then unintentionally exposed to NDMA. Conversion Ranitidine, the active ingredient in Zantac is a volatile compound.
Ranitidine can break down in the stomach, releasing NDMA as a byproduct.
But, FDA officials disagreed with the theory of conversion. According to some reports, the legal team chose this argument deliberately. They wanted to differentiate Zantac lawsuits from those of similarly contaminated valsartan. For reference, valsartan lawsuits have blamed a manufacturing defect for the NDMA contamination. Only time will tell if focusing on ranitidine conversion in the stomach will prove a successful strategy for the plaintiffs. Zantac Recall and Lawsuit Background Laboratory testing recently found a cancer-causing substance in Zantac ranitidine heartburn medication.
Valsartan, a blood pressure medication, has recently been recalled due to NDMA contamination.